Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00705939 · ClinicalTrials.gov registry record · Phase 3
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT00705939 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 45 participants.
The verdict
NCT00705939, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in the cells of the monocyte-macrophage system. This is an extension trial to Study NCT00376168 and NCT00712348.
Interventions
- DRUG Taliglucerase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00705939
The ClinicalTrials.gov registry entry for NCT00705939 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Taliglucerase alfa is the first listed.
NCT00705939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00705939 about?
NCT00705939 is a clinical study titled "Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial". Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in the cells of the monocyte...
What is the current status of trial NCT00705939?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2008-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00705939?
The interventions under investigation include: Taliglucerase alfa (DRUG).
Who is sponsoring clinical trial NCT00705939?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.